12. Lennon, G., Auffray, C., Polymeropoulos, M. & Soares, M. B. The IMAGE Consortium: an integrated molecular analysis of genomes and their expression. *Genomics* **33**, 151–152 (1996).
13. Sambrook, J., Fritsch, E. F. & Maniatis, T. *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, New York, 1989).
14. Innis, M. A., Gelfand, D. H., Sninsky, J. J. & White, T. J. (eds) *PCR Protocols: A Guide to Methods and Applications* (Academic, Orlando, 1992).
15. Miyake, K., Yamashita, Y., Ogata, M., Sudo, T. & Kimoto, M. RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. *J. Immunol.* **154**, 3333–3340 (1995).
16. Schneider, D. S., Hudson, K. L., Lin, T. Y. & Anderson, K. V. Dominant and recessive mutations define functional domains of Toll, a transmembrane protein required for dorsal–ventral polarity in the *Drosophila* embryo. *Genes Dev.* **5**, 797–807 (1991).
17. Takahashi, N., Takahashi, Y. & Putnam, F. W. Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum. *Proc. Natl Acad. Sci. USA* **82**, 1906–1910 (1985).
18. Winans, K. A. & Hashimoto, C. Ventralization of the *Drosophila* embryo by deletion of extracellular leucine-rich repeats in the Toll protein. *Mol. Biol. Cell.* **6**, 587–596 (1995).
19. Fearon, D. T. & Locksley, R. M. The instructive role of innate immunity in the acquired immune response. *Science* **272**, 50–53 (1996).
20. Medzhitov, R. & Janeway, C. A. Jr On the semantics of immune recognition. *Res. Immunol.* **147**, 208–214 (1996).
21. Yamamura, M. *et al.* Defining protective responses to pathogens: cytokine profiles in leprosy lesions. *Science* **254**, 277–279 (1991).

Acknowledgements. We thank our colleagues for discussions; P. G. Waterbury for DNA sequencing; S. Ghosh and R. Voll for pB2XLuc plasmid and for helpful suggestions; and J. Flaxenberg for assistance. We acknowledge the Howard Hughes Medical Institute and the NIAID, NIH for support of this work.

Correspondence and requests for materials should be addressed to C.A.J.Jr (e-mail: charles.janeway@yale.edu). The sequence is deposited in Genebank data base under the accession number U93091.

A protein related to splicing factor U2AF³⁵ that interacts with U2AF⁶⁵ and SR proteins in splicing of pre-mRNA

Hélène Tronchère*, Jiwu Wang* & Xiang-Dong Fu

Division of Cellular and Molecular Medicine, Department and School of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, California 92093-0651, USA

* These authors contributed equally to this work.

Recognition of a functional 3' splice site in pre-mRNA splicing requires a heterodimer of the proteins U2AF⁶⁵/U2AF³⁵. U2AF⁶⁵ binds to RNA at the polypyrimidine tract^{1,2}, whereas U2AF³⁵ is thought to interact through its arginine/serine-rich (RS) domain with other RS-domain-containing factors bound at the 5' splice site, assembled in splicing enhancer complexes, or associated with the U4/U6.U5 small nuclear ribonucleoprotein complex^{3–7}. It is unclear, however, how such network interactions can all be established through the small RS domain in U2AF³⁵. Here we describe the function of a U2AF³⁵-related protein (Urp), which is the human homologue of a mouse imprinted gene. Nuclear extracts depleted of Urp are defective in splicing, but activity can be restored by addition of recombinant Urp. U2AF³⁵ could not replace Urp in complementation, indicating that their functions do not overlap. Co-immunodepletion showed that Urp is associated with the U2AF⁶⁵/U2AF³⁵ heterodimer. Binding studies revealed that Urp specifically interacts with U2AF⁶⁵ through a U2AF³⁵-homologous region and with SR proteins (a large family of RS-domain-containing proteins) through its RS domain. Therefore, Urp and U2AF³⁵ may independently position RS-domain-containing factors within spliceosomes.

We previously purified and cloned a mammalian serine kinase, SRPK1, which is highly specific for the RS-rich superfamily of splicing factors^{8–10}. This stringent substrate specificity enabled us to do a yeast two-hybrid screen to search for new RS-domain-containing proteins. We isolated a positive clone from a HeLa complementary DNA library that contains a typical RS domain at the carboxy terminus (Fig. 1a). The recombinant protein was efficiently phosphorylated in the RS domain, like other RS-domain proteins, by

SRPK1 *in vitro* (data not shown). This protein of 483 amino acids does not contain any RNA-recognition motif characteristic of the SR family of splicing factors^{11,12}; instead, it contains two stretches of sequences, H1 and H2 (boxed in Fig. 1b), homologous to the human splicing factor U2AF³⁵. We therefore named it Urp, for U2AF³⁵-related protein. Northern blotting analysis indicates that both U2AF³⁵ and Urp are ubiquitously expressed in all human tissues and cell lines examined (data not shown). Homology searches revealed that Urp had been independently cloned from humans as U2AF1-RS2 (ref. 13), which is nearly identical (94% amino-acid identity) to another human gene, U2AF1-RS1 (ref. 13) (Fig. 1b). These two human genes are equally homologous (~80% identical) to two mouse genes¹⁴, one of which is imprinted¹⁵, and the other has a high transmission distortion in interspecific backcross progeny¹⁶. Thus, several U2AF³⁵-related proteins are expressed in mammalian cells and may be members of the superfamily of RS-domain-containing splicing factors¹¹.

To determine the function of Urp, we raised rabbit polyclonal antibodies against recombinant Urp expressed in bacteria. Immunoblotting of HeLa cell nuclear extracts demonstrated that anti-Urp antibodies specifically detect a single band of relative molecular mass 66K (Fig. 2a), which corresponds to endogenous Urp as it matches the size of Urp translated in reticulocyte lysate (data not shown). To see whether Urp is essential for splicing, we constructed affinity columns with anti-Urp antibodies or preimmune serum. Control depletion with preimmune serum had no effect, but passing nuclear extract through an anti-Urp affinity column efficiently depleted it of Urp, as evidenced by western blotting and complete inhibition of splicing (data not shown). Although this result is consistent with Urp being a splicing factor, this Urp-depleted extract could not be complemented by recombinant Urp, probably because of co-depletion of other essential splicing factors (see below). We therefore did the immunodepletion in the presence of high salt (0.5 M KCl) to minimize co-depletion. As shown in Fig. 2c, human β -globin pre-mRNA splicing in Urp-depleted nuclear extract was significantly decreased (compare lanes 1 and 2). The second step of the splicing reaction, which generates released lariat intermediate and

Figure 1 Urp structure and sequence comparison with U2AF³⁵. **a**, Amino-acid sequence of Urp. It is identical to U2AF1-RS2 (GenBank D49677; ref. 13). The two U2AF³⁵ homologous domains, H1 and H2, are boxed and amino-acid residues identical to those in U2AF³⁵ are shown in bold. Repeats of SR or RS dipeptides are underlined. **b**, Domain structure of the large and small subunits of U2AF and comparison of human U2AF³⁵, Urp/U2AF1-RS2 and U2AF1-RS1. Percentage identity between homologous domains is indicated.

ligated exons, was preferentially affected by Urp depletion under these conditions, indicating that Urp may play a role in this step; however, we could not rule out the possibility that it was required for the first step as we did not detect any accumulation of first-step splicing intermediates. To confirm the essential function of Urp in splicing, we restored Urp activity to a Urp-depleted nuclear extract with a glutathione-S-transferase (GST)-Urp fusion protein produced in baculovirus. Because Urp was insoluble in baculovirus-infected cells, we purified recombinant Urp from inclusion bodies, then isolated the protein by SDS-PAGE (Fig. 2b). After denaturation and renaturation in the presence of bovine serum albumin, recombinant Urp restored splicing activity to the Urp-depleted nuclear extract in a concentration-dependent manner (Fig. 2c, lanes 4 to 6). There was no complementing activity associated with BSA (Fig. 2c, lane 3). We conclude that Urp is an essential splicing factor.

SR proteins have redundant functions, at least *in vitro* (for review, see refs 11, 12). U2AF³⁵ was originally shown to be non-essential for constitutive splicing because U2AF⁶⁵ alone was sufficient to reconstitute a splicing-deficient nuclear extract from which the U2AF heterodimer was removed by poly(U) in the presence of high salt¹⁷. However, U2AF³⁵ is essential for constitutive and enhancer-dependent splicing by immunodepletion and reconstitution experiments⁵. Although the *Drosophila* homologue of U2AF³⁵ is required for viability¹⁸, there may be factors that are partially redundant with U2AF³⁵. Urp is such a candidate because it is related to U2AF³⁵ in structure and sequence. To test this possibility, we expressed and purified U2AF³⁵ in the same way as Urp (Fig. 2b), and found that U2AF³⁵ could not complement the Urp-depleted nuclear extract (Fig. 2c, lanes 7 to 9), indicating that Urp and U2AF³⁵ are not

functionally redundant. Results were identical when the complementation was repeated with a U2AF³⁵ protein preparation that had previously been shown to be functional in restoring splicing activity to a U2AF³⁵-depleted extract (ref. 5, and data not shown). Surprisingly, splicing in the Urp-depleted nuclear extract could be stimulated reproducibly by U2AF⁶⁵ (Fig. 2c, lanes 10 to 12). It has been found that U2AF⁶⁵ can stimulate splicing in a U2AF³⁵-deficient nuclear extract, probably as a result of recruiting the remaining U2AF³⁵ in the depleted extract⁵. U2AF⁶⁵ may therefore also interact with Urp, recruiting the remaining Urp in the Urp-depleted extract.

To test this, we examined the abundance of various splicing factors in the Urp-depleted nuclear extract by western blotting. As shown in Fig. 3a, Urp was effectively depleted by the anti-Urp affinity column in comparison to Urp present in untreated as well as preimmune serum-treated nuclear extracts. A fraction of U2AF⁶⁵ was co-depleted, consistent with an interaction between U2AF⁶⁵ and Urp. In contrast, the level of U2AF³⁵ was only slightly reduced, indicating that a large fraction of U2AF³⁵ is not associated with Urp or complexed with U2AF⁶⁵, in agreement with previous functional studies on U2AF³⁵ (ref. 5). The amount of SR proteins detected by monoclonal antibody 104 or of snRNP-associated proteins detected by anti-Sm antibodies was not affected by Urp depletion. The co-immunodepletion of Urp and U2AF⁶⁵ indicates that Urp forms a functional complex with U2AF⁶⁵ *in vivo*. This conclusion does not contradict the observation that U2AF⁶⁵ purifies only as a heterodimer with U2AF³⁵, because 2M guanidine-HCl was used in a

Figure 2 Urp is an essential splicing factor. **a**, Urp was detected in HeLa nuclear extracts (25 µg protein per lane) by anti-Urp antibodies (1:3,000) but not by the preimmune serum (1:1,000). **b**, Recombinant proteins used for complementation. All proteins were expressed in Sf9 cells. GST-Urp (lane 1) and His-U2AF³⁵ (lane 2) were purified by SDS-PAGE. Specific protein concentration was adjusted to 0.1 mg ml⁻¹. BSA (asterisks) was used as a carrier during gel elution and denaturation and renaturation. His-U2AF⁶⁵ (lane 3) was directly purified from sonicated cell lysate on a Ni²⁺ column (Invitrogen). **c**, Splicing of human β-globin pre-mRNA in control depleted (lane 1), or Urp-depleted (lanes 2-12) HeLa cell nuclear extracts (NE). The Urp-depleted nuclear extract was complemented with BSA control (9 µl, lane 2), or with three concentrations (1, 3, 9 µl) of GST-Urp (lanes 4-6), His-U2AF³⁵ (lane 7-9), or His-U2AF⁶⁵ (lane 10-12). On the right are the structures of human β-globin splicing substrate, intermediates and products: boxes, exon 1 and exon 2; thin line, intron.

Figure 3 Urp is associated with the U2AF heterodimer. **a**, 2 µl of nuclear extracts that had been depleted with preimmune serum (lane 1), anti-Urp antibodies (lane 2), or untreated (lane 3) were probed by western blotting with anti-Urp antibodies (1:3,000), anti-U2AF⁶⁵ (1:5,000), anti-U2AF³⁵ (1:5,000), mAb104 (culture supernatant), or anti-Sm (Y12, culture supernatant), as indicated on the left. Specific proteins detected by these antibodies are indicated on the right. **b**, Anti-Urp and control affinity columns (0.5 ml bed volume) were eluted with 0.5 ml of PBS plus 2M NaCl. 10 µl of eluant from each column was probed with the antibodies indicated on the left, and proteins detected are indicated on the right.

purification step¹⁹: these extreme conditions were not used in Urp depletion, so a weaker association between Urp and U2AF⁶⁵ was likely to be preserved.

We also tested for any association of Urp with other splicing factors by western blotting analysis of high-salt eluants from the control and anti-Urp affinity columns. As expected, U2AF⁶⁵, but not SR proteins or Sm antigens, was specifically detected in the eluant of the anti-Urp affinity column (Fig. 3b). U2AF³⁵ seemed to be stoichiometrically present in the Urp–U2AF⁶⁵ complex, because similar amounts of U2AF⁶⁵ and U2AF³⁵ were detected by specific antibodies of similar titres. This can be explained by the specific association of Urp with the U2AF heterodimer. Alternatively, Urp may be independently associated with equal amounts of U2AF⁶⁵ and U2AF³⁵, but we consider this less likely as only U2AF⁶⁵ binds strongly to Urp *in vitro* and in the yeast two-hybrid system (see below).

We next assayed the binding between Urp and U2AF to investigate the role of Urp in splicing. We expressed GST–U2AF³⁵ and GST–U2AF⁶⁵ in bacteria, and carried out a GST-pulldown assay using *in vitro* translated Urp, U2AF³⁵ and U2AF⁶⁵ (Fig. 4a). As expected, *in vitro* translated U2AF⁶⁵ bound strongly to GST–U2AF³⁵ immobilized on glutathione–Sephadex beads but not to vacant beads, demonstrating the specificity of binding. Under the same conditions (0.4M KCl), both Urp and U2AF³⁵ bound efficiently to immobilized U2AF⁶⁵ (Fig. 4a). The interaction between Urp and U2AF⁶⁵ was not mediated by RNA because the extent of binding was similar in the presence of RNase A (data not shown).

Interaction between Urp and U2AF⁶⁵ could be mediated by the RS domain present in both proteins as this domain is a known protein–protein–interaction interface^{3,4}, or by one or both of the U2AF³⁵ homologous domains (H1 and H2). The H2 domain in Urp is a strong candidate because the corresponding region in U2AF³⁵ is known to interact with U2AF⁶⁵ (ref. 20). We therefore prepared and tested a series of Urp mutants (Fig. 4b). Several conclusions can be drawn from the data shown in Fig. 4c and quantified in Fig. 4d. First, wild-type Urp binds to U2AF⁶⁵, but its binding is less efficient than that between U2AF⁶⁵ and U2AF³⁵; the Urp–U2AF⁶⁵ interaction was prevented in the presence of 1 M KCl (data not shown). This

explains why Urp is associated with U2AF⁶⁵ only under immuno-depletion conditions and not under the more stringent purification conditions¹⁹. Second, deletion of the RS domain from Urp has no effect on its binding to U2AF⁶⁵, indicating that the RS domain is not involved in the interaction between the two proteins. Third, although deletion of the H1 domain has no effect, deletion of the H2 domain significantly, but not completely, diminished Urp binding to U2AF⁶⁵. Thus, U2AF³⁵ and Urp seem to interact with U2AF⁶⁵ through homologous sequences. However, the interaction between Urp and U2AF⁶⁵ could not be competed by increasing amounts of unlabelled U2AF³⁵ (data not shown), supporting the idea that Urp interacts with the U2AF heterodimer *in vivo*.

To verify the sequence requirements for protein–protein interaction between Urp and U2AF⁶⁵, and to determine whether Urp, like U2AF³⁵, also interacts with SR proteins through its RS domain, we extended the binding studies to the yeast two-hybrid system. As shown in Fig. 4e, Urp interacts with U2AF⁶⁵ in yeast and deletion of the H2 domain diminishes binding, but deletion of the RS domain in Urp has no effect, consistent with the *in vitro* results. Urp, like U2AF³⁵, interacts with two SR proteins, SC35 and SF2/ASF, but not with the U1-70k protein (data not shown); deletion of the RS domain in Urp reduces its interaction with either SR protein, indicating that the interaction between Urp and SR proteins is mediated by their RS domains (Fig. 4e). Deletion of the H2 domain had no effect on the interaction between Urp and SC35. However, for unknown reasons, the removal of the H2 domains from Urp decreased its interaction with SF2/ASF. We could not detect any significant interaction between U2AF³⁵ and SF2/ASF, in contrast to a previous report³. Under the same conditions, Urp interacts with SF2/ASF, indicating a preference for SF2/ASF to bind with Urp rather than U2AF³⁵ (Fig. 4e).

We have shown that Urp is an essential splicing factor. On the basis of our finding that Urp is associated with the U2AF heterodimer in nuclear extracts and interacts with U2AF⁶⁵ and SR proteins through distinct domains, we propose that Urp may form part of a larger U2AF complex and be engaged in network interactions during spliceosome assembly. Because Urp seems to play a non-redundant function with

Figure 4 Urp interacts with U2AF⁶⁵ and SR proteins *in vitro* and in yeast. **a**, Identical amounts of *in vitro* translated ³⁵S-labelled Urp, U2AF⁶⁵ and U2AF³⁵ (top) were incubated with GST, GST–U2AF³⁵ or GST–U2AF⁶⁵ immobilized on glutathione beads (bottom). Bound proteins are indicated on the right. On the left are low-range prestained M_r markers (Bio-Rad). **b**, Organization of wild-type (WT) Urp and three deletion mutants. **c**, Binding of wild-type and mutant Urp to immobilized GST–U2AF⁶⁵. **d**, Quantification of binding efficiency. **e**, Pairwise protein–protein interaction in the yeast LexA two-hybrid system. Each number represents the average of data derived from at least three independent transformations and is expressed as fold activation above the background determined using specific bait and the empty prey vector.

Protein-protein interaction in the yeast two-hybrid system					
bait \ prey	U2AF ³⁵	Urp	UrpΔRS	UrpΔH2	U1-70K
U2AF ⁶⁵	68.0	43.0	33.6	2.4	1.1
SC35	6.5	12.8	2.4	13.7	24.1
ASF/SF2	1.0	9.2	0.7	3.0	17.5

U2AF³⁵ and appears preferentially to affect the second step of the splicing reaction, it may interact with a selective set of factors during reaction. The unique behaviour of Urp homologues in mouse indicates that Urp and its family members may be targets for regulation. □

Methods

Cloning, expression and purification. SRPK1 was cloned in pGBT9 as bait to screen a HeLa cDNA library (from G. Hannon) constructed in the pGAD-GH vector as described²¹. The initial Urp clone was lacking 92 amino acids from its N terminus, and full-length Urp cDNA was isolated from a λgt11 HeLa S3 cDNA library (Clontech).

Urp was expressed as GST fusion proteins either in bacteria or by baculovirus. Thrombin-cleaved bacterial Urp was used to raise rabbit antibodies, diluted 1:3,000 for western blotting. For splicing complementation, baculovirus-expressed Urp and U2AF were purified from the inclusion bodies of Sf9 cells, followed by isolation from SDS-PAGE. Briefly, 10⁸ infected Sf9 cells were sonicated in 10 ml buffer A (20 mM Tris, pH 7.6, 150 mM KCl, 2 mM EDTA, 1 mM DTT) plus standard protease inhibitors. Samples were centrifuged through a 15-ml sucrose cushion (40% sucrose in buffer A) at 12,000 r.p.m. for 30 min in a HB-4 rotor. Pellets were resuspended in 1 ml buffer A plus 8 M urea. An estimated 10 µg of specific protein was loaded per well onto a 10% SDS-polyacrylamide gel. Proteins were eluted from gel slices in buffer B (50 mM Tris, pH 7.5, 0.1% SDS, 0.1 mg ml⁻¹ BSA, 1 mM DTT, 0.2 mM EDTA, 0.1 mM PMSF and 2.5% glycerol) overnight at 4 °C. Eluted proteins were precipitated with four volumes of cold acetone overnight at -20 °C. After a 15-min spin, the pellet was washed with cold methanol, dried and resuspended in 2.5 µl 8 M urea. Protein was renatured by adding 125 µl buffer C (20 mM Tris, pH 7.5, 10 mM KCl, 1 mM DTT, 20 mM PMSF and 0.2 mM EDTA), incubating at 4 °C for 24 h, and dialysing for 4 h against 20 mM Tris, pH 7.9, plus 1 mM DTT. Samples were normalized to contain 0.1 mg ml⁻¹ protein, aliquoted, and stored at -80 °C.

Immunodepletion and reconstitution. Protein A-Sepharose CL-4B beads (0.5 ml; Pharmacia) were washed with PBS and mixed with an equal volume of anti-Urp serum or preimmune serum. After binding overnight, antibodies were crosslinked to protein A according to ref. 22. Antibody-bound beads were washed with 10 ml 0.1 M glycine (pH 2.5) then 2 × 10 ml buffer D (20 mM HEPES pH 7.6, 100 mM KCl, 1 mM DTT, 10% glycerol). HeLa cell nuclear extracts were used for immunodepletion as previously described³. To minimize co-depletion of other essential splicing factors, high-salt conditions were used: 1 ml nuclear extract was adjusted to 0.5 M KCl, then passed through a 0.5-ml (packed volume) antibody-affinity column 5 times at 4 °C. The depletion procedure was repeated once on a fresh 0.5-ml affinity column. Depleted extracts were dialysed against buffer D for 4 h at 4 °C, aliquoted, and stored at -80 °C. Antibody-affinity columns were regenerated by washing with 0.1 M glycine (pH 2.5) and stored in buffer D. Standard splicing reactions were carried out as described³.

In vitro and in vivo binding. U2AF⁶⁵ and U2AF³⁵ cDNAs in pSP64 and in pGEX were provided by J. Fleckner and M. Green; anti-U2AF⁶⁵ and U2AF³⁵ antisera were gifts from P. Zuo and T. Maniatis, and were used at 1:5,000 dilution. Wild-type and mutant Urp cDNAs generated by PCR were inserted downstream of the T7 promoter in pcDNA3 (Invitrogen). *In vitro*-translated proteins were prepared using a TNT kit (Promega) in the presence of [³⁵S]methionine. ³⁵S-labelled proteins were incubated with 1 µg GST-U2AF⁶⁵ or GST-U2AF³⁵ immobilized on 5 µl glutathione beads (Pharmacia) in binding buffer (20 mM HEPES, pH 7.6, 3 mM MgCl₂, 0.1 mM EDTA, 0.1% Tween, 10% glycerol, 1 mM DTT, 0.4 M KCl) plus 5% BSA at 4 °C for 1 h. After beads were washed 4 times in binding buffer, proteins were resolved on SDS-PAGE, visualized by autoradiography, and quantified on a Phosphorimager.

Two-hybrid pairwise interactions were carried out using the LexA system²³ in the host yeast strain EGY48. Bait plasmids contained individual cDNAs in frame downstream of the LexA gene in pEG202, and prey plasmids had individual cDNAs in pJG4-5. Several bait and prey plasmids (U2AF³⁵ and SF2/ASF) were gifts from J. Wu³. EGY48 cells were co-transformed by the lithium acetate method and transformants were selected on glucose/CM-ura-his-trp plates. Six randomly picked colonies were restreaked on Gal/Raff/CM-ura-his-trp plates containing X-gal for colour development. Interactions were quantified by liquid β-galactosidase assay²³.

Received 14 April; accepted 21 May 1997.

1. Ruskin, B., Zamore, P. D. & Green, M. R. A factor, U2AF, is required for U2 snRNP binding and splicing complex assembly. *Cell* **52**, 207–219 (1988).
2. Krämer, A. The structure and function of proteins involved in mammalian pre-mRNA splicing. *Annu. Rev. Biochem.* **65**, 367–490 (1996).
3. Wu, J. & Maniatis, T. Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. *Cell* **75**, 1061–1070 (1993).
4. Kohz, J. D. et al. Protein-protein interactions and 5'-splice-site recognition in mammalian mRNA precursors. *Nature* **368**, 119–124 (1994).
5. Zuo, P. & Maniatis, T. The splicing factor U2AF³⁵ mediates critical protein-protein interactions in constitutive and enhancer-dependent splicing. *Genes Dev.* **10**, 1356–1368 (1996).
6. Roscigno, R. F. & Garcia-Blanco, M. A. SR proteins escort the U4/U6.U5 tri-snRNP to the spliceosome. *RNA* **1**, 692–706 (1995).
7. Fetzter, S., Lauber, J., Will, C. L. & Lührmann, R. The [U4/U6.U5] tri-snRNP-specific 27K protein is a novel SR protein which can be phosphorylated by the snRNP-associated protein kinase. *RNA* **3**, 344–355 (1997).
8. Gui, J.-F., Lane, W. S. & Fu, X.-D. A serine kinase regulates intracellular localization of splicing factors in the cell cycle. *Nature* **369**, 678–682 (1994).
9. Gui, J.-F., Tronchère, H., Chandler, S. D. & Fu, X.-D. Purification and characterization of a kinase specific for the serine- and arginine-rich pre-mRNA splicing factors. *Proc. Natl Acad. Sci. USA* **91**, 10824–10828 (1994).
10. Colwill, K. et al. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors. *J. Biol. Chem.* **271**, 24569–24575 (1996).
11. Fu, X.-D. The superfamily of arginine/serine-rich splicing factors. *RNA* **1**, 663–680 (1995).
12. Manley, J. L. & Tacke, R. SR proteins and splicing control. *Genes Dev.* **10**, 1569–1579 (1996).
13. Kitagawa, K. et al. Isolation and mapping of human homologues of an imprinted mouse gene U2af1-rs1. *Genomics* **30**, 257–263 (1995).
14. Nabetani, A., Hatada, I., Morisaki, H., Oshimura, M. & Mukai, T. Mouse U2af1-rs1 is a neomorphic imprinted gene. *Mol. Cell. Biol.* **17**, 789–798 (1997).
15. Hyashizaki, Y. et al. Identification of an imprinted U2af binding protein related sequence on mouse chromosome 11 using the RLGs method. *Nature Genet.* **6**, 33–40 (1994).
16. Yamaoka, T., Hatada, I., Kitagawa, K., Wang, X. & Mukai, T. Cloning and mapping of the U2af1-rs2 gene with a high transmission distortion in interspecific backcross progeny. *Genomics* **27**, 337–340 (1995).
17. Zamore, P. D. & Green, M. R. Biochemical characterization of U2 snRNP auxiliary factor: an essential pre-mRNA splicing factor with novel intranuclear distribution. *EMBO J.* **10**, 207–214 (1991).
18. Rudner, D. Z., Kanaar, R., Breger, K. S. & Rio, D. C. Mutations in the small subunit of the Drosophila U2AF splicing factor cause lethality and developmental defects. *Proc. Natl Acad. Sci. USA* **93**, 10333–10337 (1996).
19. Zamore, P. D. & Green, M. R. Identification, purification, and biochemical characterization of U2 small nuclear ribonucleoprotein auxiliary factor. *Proc. Natl Acad. Sci. USA* **86**, 9243–9247 (1989).
20. Zhang, M., Zamore, P. D., Carmo-Fonseca, M., Lamond, A. I. & Green, M. R. Cloning and intracellular localization of the U2 small nuclear ribonucleoprotein auxiliary factor small subunit. *Proc. Natl Acad. Sci. USA* **89**, 8769–8773 (1992).
21. Hannon, G. J., Dmetrick, D. & Beach, D. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. *Genes Dev.* **7**, 2378–2391 (1993).
22. Harlow, E. & Lane, D. *Antibodies: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, New York, 1988).
23. Zervos, A. S., Gyuris, J. & Brent, R. Mxi, a protein that specifically interacts with Max to bind Myc-Max recognition sites. *Cell* **72**, 223–232 (1993).

Acknowledgements. We thank G. Hannon for yeast two-hybrid libraries; J.-L. Guan for raising anti-Urp antibodies; J. Fleckner and M. Green for U2AF cDNAs; P. Zuo and T. Maniatis for anti-U2AF antibodies and purified U2AF³⁵ protein; J. Wu for two-hybrid plasmids and for advice; and members of our laboratory, especially H.-Y. Wang and J. Dyck, for suggestions and contributions. X.-D.F. is a Searle Scholar. H.T. was supported by postdoctoral fellowships from the Human Frontier Science Program and La Société de Secours des Amis de la Science. J.W. was supported by a postdoctoral fellowship from the NIH. This work was supported by grants to X.-D.F. from the NIH.

Correspondence and requests for materials should be addressed to X.-D.F. (e-mail: xdfu@ucsd.edu).

correction

Expression of *Radical fringe* in limb-bud ectoderm regulates apical ectodermal ridge formation

Ed Laufer, Randall Dahn, Olivia E. Orozco, Chang-Yeol Yeo, Jacqueline Pisenti, Domingos Henrique, Ursula K. Abbott, John F. Fallon & Cliff Tabin

Nature **386**, 366–373 (1997)

We inadvertently omitted to acknowledge D. Ish-Horowitz for the Ser-2 clone and for supporting D.H. (through funds awarded by the ICRF and HFSP), and T. Vogt, S. H. Johnston, C. Rauskolb, E. Wieschaus, K. Irvine, S. Egan, Y. Rao, Y. Wang and P. Leder for sharing unpublished results. □